🇺🇸 FDA

Company profile · Sponsor

COGNITION

COGNITION THERAPEUTICS INC

CGTX · NYSE biotech PURCHASE, NY, USA
Pipeline
24
Drugs
1
Patents
8

Quick answer

COGNITION (CGTX) is a biotech company. headquartered in PURCHASE, NY, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker CGTX
Exchange NYSE
Company type biotech
Headquarters PURCHASE, NY, USA
SEC CIK 0001455365

Pipeline (24)

Search pipeline →

  1. CBD 100 mg/mL Oral Solution

    COGNITION

    Psychosis

    phase 3 small molecule active

    1 trial

  2. CBD 100 mg/mL Oral Solution

    COGNITION

    Treatment Resistant Psychosis

    phase 3 small molecule active

    1 trial

  3. Vortioxetine

    COGNITION

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  4. Active Comparator CT1812

    COGNITION

    Age-Related Macular Degeneration

    phase 2 small molecule terminated

    1 trial

  5. Active Treatment- CT1812 100 mg

    COGNITION

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  6. Autobiographical Memory Flexibility (MemFlex) training

    COGNITION

    Major Depressive Disorder

    phase 2 other completed

    1 trial

  7. C105

    COGNITION

    Cognition Disorders

    phase 2 small molecule completed

    1 trial

  8. CT1812

    COGNITION

    Alzheimer Disease

    phase 2 small molecule completed

    3 trials

  9. CT1812

    COGNITION

    Mild to Moderate Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  10. CT1812

    COGNITION

    Early Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  11. CT1812

    COGNITION

    Dementia With Lewy Bodies

    phase 2 small molecule completed

    1 trial

  12. CT1812

    COGNITION

    Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  13. Dexmedetomidine

    COGNITION

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  14. Golexanolone Placebo Capsules, oral capsules, soft, GR3027 10 mg

    COGNITION

    Primary biliary cholangitis (PBC)

    phase 2 small molecule active

    1 trial

  15. Memory Flexibility Training

    COGNITION

    Major Depressive Disorder

    phase 2 other completed

    1 trial

  16. Oxytocin nasal spray

    COGNITION

    Oxidative Stress

    phase 2 small molecule completed

    1 trial

  17. Oxytocin nasal spray

    COGNITION

    Cold Exposure

    phase 2 small molecule completed

    1 trial

  18. Psilocybin

    COGNITION

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

  19. The Modular Protocol for Mental Health

    COGNITION

    Major Depressive Disorder

    phase 2 other completed

    1 trial

  20. Vortioxetine

    COGNITION

    Post-COVID-19 Condition

    phase 2 small molecule completed

    1 trial

  21. golexanolone

    COGNITION

    Primary Biliary Cholangitis (PBC)

    phase 2 small molecule active

    1 trial

  22. 300 mg [C14] CT1812

    COGNITION

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial

  23. CT1812

    COGNITION

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  24. CT1812

    COGNITION

    Cognitive Impairment

    phase 1 small molecule completed

    1 trial

Drugs (1)

Search drugs →

  1. benzgalantamine gluconate

    ZUNVEYL

    ORAL approved

Patents (8)

Search patents →

  1. US 12208167

    Coated tablets for pH-dependent release of benzgalantamine

    Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12157743

    Solid forms of Alpha-1062 gluconate

    Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11795176

    Solid forms of Alpha-1062 gluconate

    Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11123351

    Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10603326

    Pharmaceutical formulation of 3α-ethynyl-3β-hydroxyandrostan-17-one oxime

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10351589

    3.alpha.-ethynyl, 3.beta.-hydroxy-5.alpha.-pregnan-20-oxime for use in the treatment of CNS disorders

    Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10342804

    Steroid compound for use in the treatment of hepatic encephalopathy

    Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10278977

    Methods for treating hypersomnolence

    Expires Mon May 02 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is COGNITION?

COGNITION (CGTX) is a biotech company. headquartered in PURCHASE, NY, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does COGNITION sponsor?

We track 24 ClinicalTrials.gov-linked programs for COGNITION, including CBD 100 mg/mL Oral Solution and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does COGNITION company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.